Multilayer HIV Dosage Form Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a chemically stable and bioequivalent triple combination product for HIV therapy using efavirenz, emtricitabine, and tenofovir DF is challenging due to the instability of tenofovir DF when combined with efavirenz, particularly due to the surfactant sodium lauryl sulfate, which results in inadequate bioavailability and rapid degradation.
Innovation Solution
Separating the tenofovir DF and efavirenz components to minimize contact with the surfactant, using dry granulation to maintain the crystalline form of tenofovir DF, and organizing the components in a multilayer dosage form to prevent destabilizing interactions, ensuring that the tenofovir DF is not in direct contact with the surfactant-containing efavirenz component.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If wet granulation is used to combine efavirenz, emtricitabine, and tenofovir DF into a homogeneous composition, then manufacturing ease is improved, but chemical stability deteriorates due to rapid degradation of tenofovir DF
Solution Approach 1:
The patent divides the tablet into multiple layers: a first layer containing tenofovir DF and emtricitabine, and a second layer containing efavirenz and surfactant. This segmentation prevents direct contact between tenofovir DF and the surfactant, eliminating the chemical instability issue while maintaining the benefits of combination therapy and manageable tablet size.
2Reliability
If surfactant (sodium lauryl sulfate) is included in the efavirenz formulation to achieve bioequivalence to Sustiva, then bioavailability is improved, but chemical stability deteriorates due to incompatibility with tenofovir DF
Solution Approach 1:
The patent separates the surfactant-containing efavirenz layer from the tenofovir DF layer, allowing the surfactant to perform its bioavailability-enhancing function without causing chemical degradation of tenofovir DF. The physical barrier of the layered structure prevents the harmful interaction while preserving the beneficial effect.
Solution Approach 2:
The layered tablet structure acts as an intermediary barrier between the surfactant and tenofovir DF, preventing direct contact and chemical reaction while still allowing both components to be present in the same dosage form for combined therapeutic effect.
3Device complexity
If the three APIs are combined into a unitary homogeneous composition, then device complexity is reduced, but manufacturing precision deteriorates due to inability to achieve both chemical stability and bioequivalence
Solution Approach 1:
The patent employs a segmented layered tablet structure that maintains relative simplicity while achieving precise control over drug release and stability. The first layer contains tenofovir DF and emtricitabine, and the second layer contains efavirenz and surfactant, allowing each component to function optimally without harmful interactions.
Data Source
AI summary
In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.